Kennondale Capital Management LLC Aldeyra Therapeutics, Inc. Transaction History
Kennondale Capital Management LLC
- $89.3 Billion
- Q4 2024
A detailed history of Kennondale Capital Management LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Kennondale Capital Management LLC holds 151,280 shares of ALDX stock, worth $906,167. This represents 0.85% of its overall portfolio holdings.
Number of Shares
151,280Holding current value
$906,167% of portfolio
0.85%Shares
1 transactions
Others Institutions Holding ALDX
# of Institutions
121Shares Held
36.9MCall Options Held
196KPut Options Held
142K-
Perceptive Advisors LLC New York, NY9.28MShares$55.6 Million1.31% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$32.8 Million14.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$22.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$21.7 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.88MShares$11.3 Million0.24% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $349M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...